CLLS
Cellectis S.A.
$3.63
-0.82%
$265.7M
No data for this timeframe.
Vol
Market Cap$265.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders3 funds
Inst. Value$454.2K
Inst. Activity1 buys / 0 sells
SEC Reports5
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. I0·CIK 0001627281·Prev Close $3.66
Recent Activity
May 12, 2026
SEC
Cellectis announced upcoming presentations of Phase 1 data for lasme-cel (BALLI-01) and eti-cel (NATHALI-01) at the EHA
6-K — Impact 3/10
May 4, 2026
SEC
Cellectis announced it will report Q1 2026 financial results on May 11, 2026 after market close, with no conference call
6-K — Impact 2/10
Apr 27, 2026
SEC
Cellectis announced preclinical data on its TALE-based epigenetic editing platform (TALEM) at the ASGCT annual meeting,
6-K — Impact 2/10
Inst.
BANK OF AMERICA CORP — DOUBLED
3,514 shares ($17.0K)
Inst.
WELLS FARGO & COMPANY/MN — NEAR_EXIT
3,150 shares ($9.0K)
May 20, 2026
other
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
<p align="justify">NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext
Apr 13, 2026
Press
Cellectis highlighted positive interim futility analysis results from Allogene's pivotal ALPHA3 trial of cema-cel, an al
Impact 8/10
Mar 30, 2026
Event
1:25-cv-01197 Factor Bioscience Inc. v. Cellectis, Inc. et al
Court ruling from United States District Court for the District of Delaware. Docket: N/A
Price Targets
$7.25
+99.7% upside
Strong Buy
Current $3.63
Low $4.00
Median $7.50
High $10.00
4 analysts
$4.00
$10.00
Analyst Ratings
5Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 14, 2026 | Citizens | REITERATE | Market Outperform → Market Outperform |
| Dec 23, 2025 | Clear Street | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.25 ▲ +11.9% | $-0.38 — $-0.17 | -5% YoY | 5 |
| Next Q | $-0.22 ▲ +9.2% | $-0.23 — $-0.17 | -2280% YoY | 5 |
| Current FY | $-0.83 ▲ +16.2% | $-1.01 — $-0.72 | -24% YoY | 5 |
| Next FY | $-0.90 ▼ -56.7% | $-1.32 — $-0.60 | -9% YoY | 4 |
Latest Reports
NEUTRAL
6-K
3/10
Cellectis announced upcoming presentations of Phase 1 data for lasme-cel (BALLI-01) and eti-cel (NATHALI-01) at the EHA
May 12, 2026
NEUTRAL
6-K
2/10
Cellectis announced it will report Q1 2026 financial results on May 11, 2026 after market close, with no conference call
May 4, 2026
BULLISH
Press
8/10
Cellectis highlighted positive interim futility analysis results from Allogene's pivotal ALPHA3 trial of cema-cel, an al
Apr 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $421.9K | TRIM |
| BANK OF AMERICA CORP | $17.0K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $15.2K | NEAR_EXIT |
3 institutional holders with $454.2K total value (93,840 shares) as of 2025-Q4. Top holders: MORGAN, BANK, WELLS. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 87,176 | $421.9K | 92.9% | TRIM -56.3% |
| 2 | BANK OF AMERICA CORP /DE/ | 3,514 | $17.0K | 3.7% | DOUBLED +4463.6% |
| 3 | WELLS FARGO & COMPANY/MN | 3,150 | $15.2K | 3.4% | NEAR_EXIT -81.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 77 | 3,514 | +4463.6% | $17.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 17,150 | 3,150 | -81.6% | $9.0K | 2025-Q3 |
| UBS Group AG | TRIM | 44,475 | 25,629 | -42.4% | $39.1K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 198,694 | 86,795 | -56.3% | $107.6K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 229,081 | 44,475 | -80.6% | $55.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 39,586 | 0 | -100.0% | $0.00 | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 27,322 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | NEW | — | 229,081 | — | $412.3K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 91,525 | 198,694 | +117.1% | $357.7K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 12,090 | 24,590 | +103.4% | $44.3K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.4/10.
NEUTRAL
6-K
3/10
Cellectis announced upcoming presentations of Phase 1 data for lasme-cel (BALLI-01) and eti-cel (NAT
May 12, 2026
NEUTRAL
6-K
2/10
Cellectis announced it will report Q1 2026 financial results on May 11, 2026 after market close, wit
May 4, 2026
NEUTRAL
6-K
2/10
Cellectis announced preclinical data on its TALE-based epigenetic editing platform (TALEM) at the AS
Apr 27, 2026
BULLISH
6-K
7/10
Cellectis highlighted positive interim futility data from Allogene's pivotal ALPHA3 trial for cema-c
Apr 13, 2026
NEUTRAL
COURT-RULING
3/10
Analysis based on filing metadata only — document content was unavailable
Mar 30, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 5 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.25 mean target
+99.7% upside
Strong Buy (1.75)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $3.63 |
| Target Low | $4.00 |
| Target Mean | $7.25 |
| Target Median | $7.50 |
| Target High | $10.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.75) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.25 | $-0.38 | $-0.17 | -5.0% | +11.9% | 2↑ 1↓ | $0.0B | -40.4% | 5 |
| Next Q 2026-09-30 |
$-0.22 | $-0.23 | $-0.17 | -2280.0% | +9.2% | 2↑ 1↓ | $0.0B | -60.0% | 5 |
| Current FY 2026-12-31 |
$-0.83 | $-1.01 | $-0.72 | -23.6% | +16.2% | 2↑ 1↓ | $0.0B | -28.0% | 5 |
| Next FY 2027-12-31 |
$-0.90 | $-1.32 | $-0.60 | -9.0% | -56.7% | 1↑ 0↓ | $0.1B | 14.6% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.252 | |
| 7d ago | $-0.284 | +0.032 |
| 30d ago | $-0.286 | +0.034 |
| 60d ago | $-0.272 | +0.020 |
| 90d ago | $-0.275 | +0.023 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 14, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Dec 23, 2025 | Clear Street | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
other
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
<p align="justify">NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage bio
May 12, 2026
other
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
<p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage bi
May 11, 2026
earnings
Cellectis Reports Financial Results for the First Quarter 2026
<p align="justify"><strong>Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) </strong></p>
May 6, 2026
other
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) <pre>(Article 223-16 of General Regulation of the French financial ma
May 4, 2026
earnings
Cellectis to Report First Quarter Financial Results on May 11, 2026
<p align="justify">NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage bio
Apr 27, 2026
routine
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
<p align="justify">NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage
Apr 13, 2026
fda
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
<p align="justify">NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-sta
Apr 7, 2026
other
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) <pre>(Article 223-16 of General Regulation of the French financial ma
Mar 30, 2026
Enforcement
1:25-cv-01197 Factor Bioscience Inc. v. Cellectis, Inc. et al
Court ruling from United States District Court for the District of Delaware. Docket: N/A
Mar 19, 2026
earnings
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
<p align="justify">NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage
Mar 12, 2026
earnings
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
<p align="justify">NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage b
Mar 4, 2026
other
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) <pre>(Article 223-16 of General Regulation of the French financial ma